NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. SPY
3. PBA
4. ALAR
5. CCH:LN
6. META
7. CCHGY
8. PRY:IM
9. PRYMY
10. SKA-B

Go back to NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
(NASDAQ: NRSN) Delayed: 0.71 -0.01 (1.39%)
Previous Close $0.72    52 Week High $ 
Open $0.75    52 Week Low $ 
Day High $0.75    P/E N/A 
Day Low $0.67    EPS $ 
Volume 231,788